The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC.
Philip C. Mack
No relevant relationships to disclose
James Moon
No relevant relationships to disclose
Howard Jack West
No relevant relationships to disclose
Wilbur A. Franklin
No relevant relationships to disclose
Marileila Varella-Garcia
Other Remuneration - Biomarker Patent
Murry W. Wynes
No relevant relationships to disclose
Antoinette J. Wozniak
Honoraria - Genentech
Research Funding - Genentech
Mary Weber Redman
No relevant relationships to disclose
Fred R. Hirsch
Consultant or Advisory Role - Genentech
Research Funding - OSI Pharmaceuticals
Other Remuneration - Biomarker Patent
David R. Gandara
Consultant or Advisory Role - Genentech
Research Funding - Genentech